FluGen, of Madison, has received $7.8 million to begin human clinical trials, probably this fall, of its product: a painless, microneedle skin patch the size of a poker chip that will be used to deliver vaccines against influenza and other illnesses. Its technology is licensed through the Wisconsin Alumni Research Foundation.
Office of Strategic Communication